Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report

Savolitinib is a tyrosine kinase inhibitor being developed for the treatment of metastatic non–small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) factor exon 14 skipping alterations. However, the role of savolitinib in neoadjuvant therapy for lung cancer remains unclear. Her...

Full description

Bibliographic Details
Main Authors: Yu Zhang, Hao Zhang, Hanqing Wang, Jingtong Zeng, Bo Zhang, Ning Zhou, Lingling Zu, Zuoqing Song, Changli Wang, Song Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
savolitinib
neoadjuvant
NSCLC
MET exon 14 skipping
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.968030/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.968030/full

Similar Items